BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Hepatol. Oct 27, 2026; 18(10): 124793
Published online Oct 27, 2026. doi: 10.4254/wjh.124793
Table 5 Autoantibody profile and discriminatory value in the diagnosis of autoimmune hepatitis vs lupus hepatitis in patients with systemic lupus erythematosus
Autoantibody
Sensitivity in AIH
Specificity for AIH
Prevalence in SLE
Discriminatory value in AIH-SLE
Clinical notes
ANA80%Low95%-99%NoneIntrinsic to SLE; not useful for discrimination
Anti-SMA (VG/VGT)63%ModerateApproximately 4.4%HighVG/VGT immunofluorescence pattern strongly favours AIH; anti-F-actin ELISA: AUROC 0.88
Anti-SLA/LP14%-20%99%Not reportedVery highOnly AIH-specific autoantibody; sole marker in 14%-20% of AIH; associated with higher biochemical response rates; target antigen: SepSecS
Anti-LKM13% (type 2 AIH)HighRareHigh if presentMarker of type 2 AIH; predominantly paediatric; target antigen: CYP2D6
Anti-ribosomal P0%High for lupus hepatitis10%-40%High-favours lupus hepatitisPresent in 68.8% of lupus hepatitis vs 0% of primary AIH; OR approximately 5.4 for hepatic SLE involvement (meta-analysis)
Polyreactive IgG75%-88% (including seronegative AIH)HighNot studiedPotentially high25%-14% higher specificity than ANA/SMA; present in 88% of seronegative AIH; returns to baseline on treatment; not studied in SLE-AIH overlap
Anti-MRPS2761.8%87.1%Not studiedUnknownNovel biomarker identified by human proteome microarray; titres unchanged with treatment; role in AIH-SLE overlap unexplored


Write to the Help Desk